BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 11, 2026
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Abliva’s NV-354 awarded US orphan drug designation for mitochondrial disease
To read the full story,
subscribe
or
sign in
.
Endocrine/Metabolic
Abliva’s NV-354 awarded US orphan drug designation for mitochondrial disease
April 18, 2023
Abliva AB’s NV-354 has been granted orphan drug designation by the FDA for the treatment of mitochondrial disease.
BioWorld Science
Endocrine/metabolic
FDA
Orphan drug